China Hemangioblastoma Market

ID: MRFR/HC/54546-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026
China Hemangioblastoma Market Research Report By Tumor Site (Brain, Spinal Cord, Retina), By Diagnosis (CT Scan, MRI Scan, Others) and By Treatment (Surgery, Chemotherapy, Radiotherapy, Corticosteroids, Anticonvulsants, Others) - Growth & Industry Forecast 2025 To 2035
China Hemangioblastoma Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.01%
2024 Market Size$ 199.66 Million
2025 Market Size$ 219.64 Million
2035 Market Size$ 570 Million
Key Players
Roche
Novartis
Bristol-Myers Squibb
Merck & Co.
Pfizer
Eli Lilly and Company
Trends
  • Emergence of Targeted Therapies
  • Advancements in Surgical Techniques
  • Increased Research Funding
Opportunities
  • Growing Awareness and Education
  • Government Initiatives and Support
  • Rising Incidence of Hemangioblastoma
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Tumor Site (USD Million)
      1. 4.1.1 Brain
      2. 4.1.2 Spinal Cord
      3. 4.1.3 Retina
    2. 4.2 Food, Beverages & Nutrition, BY Diagnosis (USD Million)
      1. 4.2.1 CT Scan
      2. 4.2.2 MRI Scan
      3. 4.2.3 Angiogram
    3. 4.3 Food, Beverages & Nutrition, BY Treatment (USD Million)
      1. 4.3.1 Surgery
      2. 4.3.2 Chemotherapy
      3. 4.3.3 Radiotherapy
      4. 4.3.4 Corticosteroids
      5. 4.3.5 Anticonvulsants
    4. 4.4 Food, Beverages & Nutrition, BY Radiotherapy (USD Million)
      1. 4.4.1 Conformal Radiotherapy
      2. 4.4.2 Intensity Modulated Radiotherapy (IMRT)
      3. 4.4.3 Stereotactic Radiotherapy
      4. 4.4.4 Radiosurgery
    5. 4.5 Food, Beverages & Nutrition, BY Corticosteroids (USD Million)
      1. 4.5.1 Hydrocortisone
      2. 4.5.2 Dexamethasone
      3. 4.5.3 Methylprednisolone
      4. 4.5.4 Prednisolone
    6. 4.6 Food, Beverages & Nutrition, BY Anticonvulsants (USD Million)
      1. 4.6.1 Carbamazepine
      2. 4.6.2 Lamotrigine
      3. 4.6.3 Levetiracetam
      4. 4.6.4 Phenytoin
      5. 4.6.5 Sodium Valproate
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Merck & Co. (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly and Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Amgen (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AstraZeneca (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 CHINA MARKET ANALYSIS BY TUMOR SITE
    3. 6.3 CHINA MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 CHINA MARKET ANALYSIS BY TREATMENT
    5. 6.5 CHINA MARKET ANALYSIS BY RADIOTHERAPY
    6. 6.6 CHINA MARKET ANALYSIS BY CORTICOSTEROIDS
    7. 6.7 CHINA MARKET ANALYSIS BY ANTICONVULSANTS
    8. 6.8 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    9. 6.9 RESEARCH PROCESS OF MRFR
    10. 6.10 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    11. 6.11 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    12. 6.12 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    13. 6.13 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY TUMOR SITE, 2024 (% SHARE)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY TUMOR SITE, 2024 TO 2035 (USD Million)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 (% SHARE)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
    20. 6.20 FOOD, BEVERAGES & NUTRITION, BY RADIOTHERAPY, 2024 (% SHARE)
    21. 6.21 FOOD, BEVERAGES & NUTRITION, BY RADIOTHERAPY, 2024 TO 2035 (USD Million)
    22. 6.22 FOOD, BEVERAGES & NUTRITION, BY CORTICOSTEROIDS, 2024 (% SHARE)
    23. 6.23 FOOD, BEVERAGES & NUTRITION, BY CORTICOSTEROIDS, 2024 TO 2035 (USD Million)
    24. 6.24 FOOD, BEVERAGES & NUTRITION, BY ANTICONVULSANTS, 2024 (% SHARE)
    25. 6.25 FOOD, BEVERAGES & NUTRITION, BY ANTICONVULSANTS, 2024 TO 2035 (USD Million)
    26. 6.26 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TUMOR SITE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY RADIOTHERAPY, 2025-2035 (USD Million)
      5. 7.2.5 BY CORTICOSTEROIDS, 2025-2035 (USD Million)
      6. 7.2.6 BY ANTICONVULSANTS, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

China Hemangioblastoma Market Segmentation

China Hemangioblastoma Market By Tumor Site (USD Million, 2025-2035)

  • Brain
  • Spinal Cord
  • Retina

China Hemangioblastoma Market By Diagnosis (USD Million, 2025-2035)

  • CT Scan
  • MRI Scan
  • Angiogram

China Hemangioblastoma Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Corticosteroids
  • Anticonvulsants

China Hemangioblastoma Market By Radiotherapy (USD Million, 2025-2035)

  • Conformal Radiotherapy
  • Intensity Modulated Radiotherapy (IMRT)
  • Stereotactic Radiotherapy
  • Radiosurgery

China Hemangioblastoma Market By Corticosteroids (USD Million, 2025-2035)

  • Hydrocortisone
  • Dexamethasone
  • Methylprednisolone
  • Prednisolone

China Hemangioblastoma Market By Anticonvulsants (USD Million, 2025-2035)

  • Carbamazepine
  • Lamotrigine
  • Levetiracetam
  • Phenytoin
  • Sodium Valproate

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.